GSK plc (GSK) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 16, 2026
Summary
GSK’s revenue went from $34.3B in fiscal 2016 to $44.0B in fiscal 2025, growth of about 2.8% a year.
Net income in fiscal 2025 was $7.7B, a net margin of 17.5%; the best year in this period was 2022 with $18.0B.
Over the twelve months to September 30, 2026, revenue was $44.3B and net income $5.7B.
Free cash flow was $8.6B in fiscal 2025 and positive in 10 of the 10 years shown.
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $44.3B | $44.0B | $39.3B | $38.6B | $35.3B | $33.3B | $33.2B | $44.6B | $39.5B | $40.8B | $34.3B |
| Gross profit | — | $31.8B | $28.0B | $27.7B | $23.8B | $22.3B | $22.4B | $28.9B | $26.3B | $26.8B | $22.9B |
| Operating income | — | $10.7B | $5.0B | $8.6B | $7.7B | $5.9B | $8.2B | $9.2B | $7.0B | $5.5B | $3.2B |
| Net income | $5.7B | $7.7B | $3.2B | $6.3B | $18.0B | $5.9B | $7.8B | $6.1B | $4.6B | $2.1B | $1.1B |
| EPS (diluted) | $2.82 | $3.81 | $1.59 | $3.10 | $8.89 | $2.92 | $3.88 | $3.03 | $2.29 | $1.02 | $0.56 |
| R&D | — | — | — | — | — | — | — | — | — | — | — |
| Revenue growth | — | +11.9% | +1.9% | +9.3% | +5.9% | +0.1% | −25.4% | +13.0% | −3.3% | +18.8% | −3.2% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $11.8B | $10.4B | $8.2B | $8.6B | $8.9B | $10.7B | $11.5B | $10.6B | $10.8B | $9.4B | $8.0B |
| Capital spending | -$3.5B | -$1.8B | -$1.8B | -$1.7B | -$1.4B | -$1.3B | -$1.3B | -$1.7B | -$1.7B | -$2.1B | -$1.9B |
| Free cash flow | $8.3B | $8.6B | $6.5B | $6.9B | $7.5B | $9.4B | $10.2B | $8.9B | $9.1B | $7.3B | $6.1B |
| Dividends paid | $3.6B | $3.5B | $3.1B | $2.9B | $4.2B | $5.4B | $5.4B | $5.2B | $5.0B | $5.3B | $6.0B |
| Buybacks | — | $1.9B | $0 | $0 | — | — | — | — | — | — | — |
| Stock-based pay | — | $504M | $431M | $390M | $416M | $462M | $460M | $482M | $461M | $450M | $393M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $4.6B | $4.8B | $3.7B | $4.5B | $5.8B | $8.6B | $6.2B | $5.0B | $5.2B | $6.0B |
| Debt | — | $23.9B | $21.3B | $22.9B | $25.2B | $32.6B | $37.1B | $40.3B | $33.4B | $23.1B | $23.1B |
| Equity | — | $22.1B | $17.1B | $17.0B | $12.7B | $20.3B | $19.9B | $15.1B | $4.8B | -$92M | $1.4B |
| Total assets | — | $82.3B | $74.5B | $75.0B | $72.3B | $106.6B | $109.8B | $105.2B | $74.3B | $76.2B | $72.7B |
| Shares (diluted) | 2.04B | 2.02B | 2.02B | 2.02B | 2.02B | 2.02B | 2.02B | 2.02B | 2.02B | 2.02B | 2.02B |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | 72.4% | 71.2% | 71.8% | 67.4% | 67.0% | 67.4% | 64.8% | 66.8% | 65.7% | 66.7% |
| Operating margin | — | 24.3% | 12.8% | 22.2% | 21.9% | 17.6% | 24.6% | 20.6% | 17.8% | 13.5% | 9.3% |
| Net margin | 13.0% | 17.5% | 8.2% | 16.2% | 51.0% | 17.8% | 23.6% | 13.8% | 11.8% | 5.1% | 3.3% |
| FCF margin | 18.7% | 19.6% | 16.4% | 18.0% | 21.3% | 28.3% | 30.6% | 20.0% | 23.0% | 17.8% | 17.8% |
| ROIC | — | 19.8% | 11.1% | 18.8% | 17.8% | 10.8% | 14.1% | 14.1% | 15.5% | 14.8% | 7.1% |
| ROE | — | 34.9% | 18.8% | 36.9% | 141.1% | 29.1% | 39.4% | 40.7% | 95.8% | -2252.9% | 81.1% |
Frequently asked questions
What is GSK’s annual revenue?
$44.0B in fiscal 2025 and $44.3B over the twelve months to September 30, 2026.
How much profit does GSK make?
Net income was $7.7B in fiscal 2025 (net margin 17.5%).
Is GSK’s revenue growing?
Yes: revenue rose 11.9% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.